Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) a biopharmaceutical company will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 8:30 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.alnylam.com
Earnings Expectation
Alnylam Pharmaceuticals, Inc. a biopharmaceutical company, is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 1.66 per share from $ 120.75 million in revenue. For the full year, analysts predict revenues of $ 469.94 million, while looking forward to loss of $ 6.46 per share.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The companys pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
